Landscape Capital Management L.L.C. Acquires New Stake in Elanco Animal Health

Landscape Capital Management L.L.C. has joined the roster of investors in Elanco Animal Health Incorporated (NYSE: ELAN), acquiring 114,471 shares during the second quarter of 2026, valued at approximately $2,817,000. This transaction underscores the ongoing interest from institutional investors in the animal health sector, where hedge funds and large institutions currently own 97.48% of the company's total outstanding stock.

Beyond Landscape Capital Management, other investment entities have also been actively adjusting their portfolios. NewEdge Advisors LLC increased its stake by 133.7%, while Root Financial Partners LLC raised its position by 50.7%. New positions in the company were also established by Mitsubishi UFJ Asset Management Co. Ltd., Uniplan Investment Counsel Inc., and Torren Management LLC, confirming a robust market interest in Elanco's operational trajectory.

Elanco's financial performance remains a focal point for market analysts. As of August 22, 2026, the company's market capitalization reached $12.02 billion. In its latest quarterly earnings report released on August 5, the company posted earnings per share (EPS) of $0.34, exceeding analyst consensus estimates of $0.27 by $0.07. Revenue for the quarter totaled $1.37 billion, reflecting a year-over-year increase of 10.2%.

Internal shifts in ownership structure also highlight leadership's confidence in the company's future. In August, Director Paul Herendeen acquired 10,000 shares at a value of $236,800, and CFO Robert M. Vanhimbergen purchased an additional 4,200 shares for $96,936. Over the last 90 days, company insiders have purchased 63,198 shares, signaling management's faith in the firm's long-term growth potential and stability.

Market analysts maintain a cautiously optimistic outlook regarding Elanco stock. UBS Group raised its target price to $33, while KeyCorp and JPMorgan Chase & Co. increased their price objectives to $30. Currently, the average rating for the stock, according to MarketBeat, is a "Moderate Buy," with a consensus price target of $29.09 per share, compared to current market trading levels around the $24 mark.